Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma

Article Article scientifique Article Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma eng 2014 author Hottinger A F author Ben Aissa Assma 746412 author Espeli Vittoria 744325 author Squiban D author Dunkel Nathalie 592602 author Vargas Gomez Maria Isabel 503296 author Hundsberger T author Mach Nicolas 32943 author Schaller Karl Lothard 658606 author Weber D C author Bodmer A author Dietrich Pierre-Yves 96532 2655-2661 10.1038/bjc.2014.209 24786603 0007-0920 Sorafenib (Sb) is a multiple kinase inhibitor targeting both tumour cell proliferation and angiogenesis that may further act as a potent radiosensitizer by arresting cells in the most radiosensitive cell cycle phase. This phase I open-label, noncontrolled dose escalation study was performed to determine the safety and maximum tolerated dose (MTD) of Sb in combination with radiation therapy (RT) and temozolomide (TMZ) in 17 patients with newly diagnosed high-grade glioma. Adult Aged Antineoplastic Combined Chemotherapy Protocols/pharmacokinetics/therapeutic use/toxicity Brain Neoplasms/mortality/therapy Chemoradiotherapy Dacarbazine/administration & dosage/analogs & derivatives Disease-Free Survival Female Glioblastoma/mortality/therapy Humans Male Maximum Tolerated Dose Middle Aged Niacinamide/administration & dosage/analogs & derivatives Phenylurea Compounds/administration & dosage Treatment Outcome Dewey 616.8 Dewey 616.0757 Dewey 616 56 Département de médecine 221 61 Département des neurosciences cliniques 226 62 Département de radiologie et informatique médicale 227 false 513 Groupe Schaller Karl Lothard (neurochirurgie) 851 27 Immunothérapie des cancers 42 560 Génétique 901 British journal of cancer 110 11 fa1f60c1-dd9b-47fb-a5cf-9e924b8fc23b Article (Published version) Public Phase I study of sorafenib combined with.pdf 472952 application/pdf CC BY-NC-SA db221807-4468-4ce3-bc9e-2df26af413a6 Erratum Public bjc2017469.pdf 48940 application/pdf CC BY-NC-SA Published erratum : Hottinger AF, Ben Aissa A, Espeli V, Squiban D, Dunkel N, Vargas MI, Hundsberger T, Mach N, Schaller K, Weber DC, Bodmer A, Dietrich PY. Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma. Br J Cancer. 2018 Mar 20;118(6):e10. Erratum for: Br J Cancer. 2014 May 27;110(11):2655-61. 10.1038/bjc.2017.469 29315292 openAccess Faculté de médecine / Section de médecine clinique / Département de médecine Faculté de médecine / Section de médecine clinique / Département des neurosciences cliniques Faculté de médecine / Section de médecine clinique / Département de radiologie et informatique médicale

Title	Published in	Access level	OA Policy	Year	Views	Downloads

Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma	British journal of cancer			2014	673	238

Archive ouverte UNIGE

Espeli, Vittoria